Trial Profile
Phase II evaluation of gemtuzumab ozogamicin in combination with cytarabine in untreated patients above the age of 60 years with acute myeloid leukemia and high-risk myelodysplastic syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2013
Price :
$35
*
At a glance
- Drugs Cytarabine (Primary) ; Gemtuzumab ozogamicin (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 22 Sep 2006 Status change
- 25 Nov 2005 New trial record.